Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 3 | 2015 | 68 | 0.920 |
Why?
|
| HIV Infections | 4 | 2021 | 2303 | 0.920 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2021 | 2 | 0.830 |
Why?
|
| Mitochondrial Diseases | 1 | 2021 | 16 | 0.820 |
Why?
|
| Fibroblast Growth Factors | 1 | 2021 | 33 | 0.810 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2013 | 21 | 0.750 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2019 | 31 | 0.690 |
Why?
|
| Adipocytes | 1 | 2019 | 58 | 0.670 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 196 | 0.650 |
Why?
|
| Insulin Resistance | 1 | 2020 | 184 | 0.640 |
Why?
|
| T-Lymphocytes | 3 | 2021 | 357 | 0.600 |
Why?
|
| Major Histocompatibility Complex | 2 | 2012 | 21 | 0.530 |
Why?
|
| Wolves | 1 | 2013 | 2 | 0.460 |
Why?
|
| Antigen Presentation | 1 | 2013 | 54 | 0.450 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 83 | 0.430 |
Why?
|
| Peptides | 2 | 2012 | 320 | 0.420 |
Why?
|
| Histocompatibility Antigens | 1 | 2012 | 13 | 0.420 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2012 | 29 | 0.420 |
Why?
|
| Immunotherapy | 2 | 2015 | 95 | 0.410 |
Why?
|
| Autoimmunity | 1 | 2012 | 53 | 0.410 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2016 | 159 | 0.380 |
Why?
|
| Mitochondria | 3 | 2021 | 487 | 0.330 |
Why?
|
| Dogs | 3 | 2013 | 149 | 0.310 |
Why?
|
| Cohort Studies | 2 | 2020 | 1492 | 0.270 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 2721 | 0.240 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2016 | 259 | 0.240 |
Why?
|
| Child | 2 | 2021 | 3131 | 0.220 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2022 | 21 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2021 | 234 | 0.210 |
Why?
|
| Adolescent | 3 | 2021 | 5363 | 0.200 |
Why?
|
| Humans | 12 | 2021 | 37093 | 0.200 |
Why?
|
| Protein Multimerization | 2 | 2012 | 103 | 0.190 |
Why?
|
| Risk | 1 | 2021 | 267 | 0.190 |
Why?
|
| Ethanolamine | 1 | 2021 | 8 | 0.190 |
Why?
|
| Anti-Retroviral Agents | 1 | 2021 | 147 | 0.190 |
Why?
|
| Regression Analysis | 1 | 2021 | 455 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 448 | 0.180 |
Why?
|
| Phospholipids | 1 | 2021 | 70 | 0.180 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 225 | 0.180 |
Why?
|
| Subcutaneous Fat | 1 | 2019 | 15 | 0.170 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2019 | 57 | 0.170 |
Why?
|
| Animals | 9 | 2022 | 15081 | 0.170 |
Why?
|
| Cytokines | 2 | 2021 | 602 | 0.170 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 974 | 0.170 |
Why?
|
| Selenoproteins | 1 | 2021 | 159 | 0.160 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 175 | 0.160 |
Why?
|
| Infant | 1 | 2021 | 1046 | 0.160 |
Why?
|
| Child, Preschool | 1 | 2021 | 1418 | 0.150 |
Why?
|
| Mice | 6 | 2022 | 5913 | 0.140 |
Why?
|
| Chemotaxis | 1 | 2016 | 60 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 55 | 0.140 |
Why?
|
| Antibodies | 1 | 2016 | 141 | 0.140 |
Why?
|
| Alleles | 2 | 2013 | 321 | 0.130 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 420 | 0.130 |
Why?
|
| Male | 6 | 2021 | 20025 | 0.130 |
Why?
|
| Immune Tolerance | 1 | 2015 | 65 | 0.130 |
Why?
|
| Female | 4 | 2021 | 20969 | 0.120 |
Why?
|
| Amino Acid Sequence | 2 | 2013 | 1180 | 0.110 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 1568 | 0.110 |
Why?
|
| Phylogeny | 2 | 2013 | 644 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2013 | 130 | 0.110 |
Why?
|
| Bicycling | 3 | 2007 | 17 | 0.110 |
Why?
|
| Biological Assay | 1 | 2012 | 59 | 0.110 |
Why?
|
| Molecular Imaging | 1 | 2012 | 30 | 0.100 |
Why?
|
| Young Adult | 1 | 2021 | 4268 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 191 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 515 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2013 | 387 | 0.090 |
Why?
|
| Dietary Carbohydrates | 2 | 2006 | 31 | 0.090 |
Why?
|
| Cell Line | 1 | 2013 | 1354 | 0.090 |
Why?
|
| Aged | 1 | 2019 | 6741 | 0.080 |
Why?
|
| Adult | 4 | 2019 | 11712 | 0.080 |
Why?
|
| Physical Exertion | 1 | 2007 | 26 | 0.070 |
Why?
|
| Immune System | 1 | 2007 | 41 | 0.070 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2006 | 14 | 0.070 |
Why?
|
| Interleukin-8 | 1 | 2006 | 60 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2006 | 75 | 0.070 |
Why?
|
| Leukocytes | 1 | 2006 | 72 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2006 | 153 | 0.070 |
Why?
|
| Middle Aged | 1 | 2019 | 10129 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2012 | 1908 | 0.060 |
Why?
|
| Phenylephrine | 1 | 2022 | 36 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2022 | 97 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1207 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 159 | 0.050 |
Why?
|
| Collagen | 1 | 2022 | 172 | 0.050 |
Why?
|
| Proteome | 1 | 2022 | 144 | 0.050 |
Why?
|
| Ethanolamines | 1 | 2021 | 12 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 47 | 0.050 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2021 | 21 | 0.050 |
Why?
|
| Lipogenesis | 1 | 2021 | 18 | 0.050 |
Why?
|
| Phosphatidylethanolamines | 1 | 2021 | 27 | 0.050 |
Why?
|
| Lymphocytes | 2 | 2015 | 118 | 0.050 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2021 | 72 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2022 | 272 | 0.050 |
Why?
|
| Exercise | 1 | 2006 | 613 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 67 | 0.050 |
Why?
|
| Glycolysis | 1 | 2021 | 68 | 0.050 |
Why?
|
| Metabolomics | 1 | 2021 | 81 | 0.050 |
Why?
|
| Myocardium | 1 | 2022 | 235 | 0.050 |
Why?
|
| Calcium | 1 | 2022 | 480 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2021 | 933 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 8 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 45 | 0.040 |
Why?
|
| Epinephrine | 2 | 2006 | 36 | 0.040 |
Why?
|
| Pregnancy | 1 | 2021 | 1549 | 0.030 |
Why?
|
| Killer Cells, Natural | 2 | 2007 | 92 | 0.030 |
Why?
|
| Hydrocortisone | 2 | 2006 | 78 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1198 | 0.030 |
Why?
|
| Insulin-Secreting Cells | 1 | 2015 | 28 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 185 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 204 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 290 | 0.030 |
Why?
|
| Breeding | 1 | 2012 | 21 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2012 | 87 | 0.030 |
Why?
|
| Homozygote | 1 | 2012 | 77 | 0.030 |
Why?
|
| Epitopes | 1 | 2012 | 148 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2012 | 90 | 0.030 |
Why?
|
| Inflammation | 1 | 2016 | 618 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2012 | 195 | 0.030 |
Why?
|
| Haplotypes | 1 | 2012 | 182 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 265 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2012 | 381 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 972 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2012 | 808 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1015 | 0.020 |
Why?
|
| Exercise Test | 1 | 2007 | 67 | 0.020 |
Why?
|
| Placebos | 1 | 2006 | 37 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 41 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2006 | 77 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 2231 | 0.020 |
Why?
|
| Neutrophils | 1 | 2006 | 131 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 236 | 0.020 |
Why?
|
| Insulin | 1 | 2006 | 236 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2006 | 353 | 0.020 |
Why?
|
| Monocytes | 1 | 2006 | 257 | 0.010 |
Why?
|
| United States | 1 | 2007 | 4223 | 0.010 |
Why?
|